499 related articles for article (PubMed ID: 18025850)
1. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J
Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850
[TBL] [Abstract][Full Text] [Related]
2. Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: a long-term study.
Salinas-Sánchez AS; Lorenzo-Romero JG; Giménez-Bachs JM; Sánchez-Sánchez F; Donate-Moreno MJ; Rubio-Del-Campo A; Hernández-Millán IR; Segura-Martín M; Atienzar-Tobarra M; Escribano-Martínez J
Urol Oncol; 2008; 26(6):620-6. PubMed ID: 18367096
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implications of p53 gene mutations in bladder tumors.
Lorenzo-Romero JG; Salinas-Sánchez AS; Giménez-Bachs JM; Sánchez-Sánchez F; Escribano-Martínez J; Segura-Martín M; Hernandez-Millán IR; Virseda-Rodríguez JA
J Urol; 2003 Feb; 169(2):492-9. PubMed ID: 12544295
[TBL] [Abstract][Full Text] [Related]
4. p53 Gene mutations in superficial bladder cancer.
Lorenzo Romero JG; Salinas Sánchez AS; Giménez Bachs JM; Sánchez Sánchez F; Escribano Martínez J; Hernández Millán IR; Segura Martín M; Virseda Rodríguez JA
Urol Int; 2004; 73(3):212-8. PubMed ID: 15539839
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
Dekairelle AF; Tombal B; Cosyns JP; Gala JL
Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
[TBL] [Abstract][Full Text] [Related]
7. Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma.
Tiguert R; Bianco FJ; Oskanian P; Li Y; Grignon DJ; Wood DP; Pontes JE; Sarkar FH
J Urol; 2001 Dec; 166(6):2155-60. PubMed ID: 11696726
[TBL] [Abstract][Full Text] [Related]
8. p53 gene mutation in recurrent superficial bladder cancer.
Yoshimura I; Kudoh J; Saito S; Tazaki H; Shimizu N
J Urol; 1995 May; 153(5):1711-5. PubMed ID: 7715016
[TBL] [Abstract][Full Text] [Related]
9. P53 mutation predicts intravesical adriamycin instillation failure in superficial transitional cell carcinoma of bladder.
Shiraishi K; Eguchi S; Mohri J; Kamiryo Y
Anticancer Res; 2003; 23(4):3475-8. PubMed ID: 12926093
[TBL] [Abstract][Full Text] [Related]
10. p53 mutation is infrequent in clear cell carcinoma of the ovary.
Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
[TBL] [Abstract][Full Text] [Related]
11. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer.
George B; Datar RH; Wu L; Cai J; Patten N; Beil SJ; Groshen S; Stein J; Skinner D; Jones PA; Cote RJ
J Clin Oncol; 2007 Dec; 25(34):5352-8. PubMed ID: 18048815
[TBL] [Abstract][Full Text] [Related]
12. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY.
Watanabe J; Nishiyama H; Okubo K; Takahashi T; Toda Y; Habuchi T; Kakehi Y; Tada M; Ogawa O
Urology; 2004 May; 63(5):989-93. PubMed ID: 15135005
[TBL] [Abstract][Full Text] [Related]
14. p53 mutations in multiple urothelial carcinomas: a molecular analysis of the development of multiple carcinomas.
Goto K; Konomoto T; Hayashi K; Kinukawa N; Naito S; Kumazawa J; Tsuneyoshi M
Mod Pathol; 1997 May; 10(5):428-37. PubMed ID: 9160306
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas.
Bernardini S; Adessi GL; Billerey C; Chezy E; Carbillet JP; Bittard H
J Urol; 1999 Oct; 162(4):1496-501. PubMed ID: 10492244
[TBL] [Abstract][Full Text] [Related]
16. Novel p21WAF1/CIP1 mutations in superficial and invasive transitional cell carcinomas.
Malkowicz SB; Tomaszewski JE; Linnenbach AJ; Cangiano TA; Maruta Y; McGarvey TW
Oncogene; 1996 Nov; 13(9):1831-7. PubMed ID: 8934528
[TBL] [Abstract][Full Text] [Related]
17. Expression of bcl-2 and bcl-X in bladder cancer.
Kirsh EJ; Baunoch DA; Stadler WM
J Urol; 1998 Apr; 159(4):1348-53. PubMed ID: 9507882
[TBL] [Abstract][Full Text] [Related]
18. Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects.
Vet JA; Bringuier PP; Schaafsma HE; Witjes JA; Debruyne FM; Schalken JA
Lab Invest; 1995 Dec; 73(6):837-43. PubMed ID: 8558845
[TBL] [Abstract][Full Text] [Related]
19. [The molecular biology of bladder carcinoma].
Moreno Sierra J; Maestro de las Casas ML; Chicharro Almarza J; Ortega Heredia MD; López García-Asenjo J; Merino Sánchez C; Blanco Jiménez E; Silmi Moyano A; Rsesel Estévez L
Arch Esp Urol; 1997 Oct; 50(8):855-66. PubMed ID: 9463283
[TBL] [Abstract][Full Text] [Related]
20. Activation of RAS family genes in urothelial carcinoma.
Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
